Epix Seeks New Vasovist Partner After Bayer Backs Out
This article was originally published in The Pink Sheet Daily
Executive Summary
Focus on competing Magnevist could have prompted Bayer Schering’s decision.
You may also be interested in...
Gadolinium Imaging Agents To Get Safety Review At FDA Advisory Committee
Sponsors are conducting mandatory clinical trials on the risk for patients with moderate to severe renal insufficiency.
Gadolinium Imaging Agents To Get Safety Review At FDA Advisory Committee
Sponsors are conducting mandatory clinical trials on the risk for patients with moderate to severe renal insufficiency.
Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?
Marrying off drugs inherited in Predix merger could help firm stay afloat.